deferasirox has been researched along with Cirrhosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eguchi, A; Fujii, A; Hirotani, S; Iwasaku, T; Masuyama, T; Morisawa, D; Naito, Y; Oboshi, M; Okuhara, Y; Sawada, H | 1 |
| Alimena, G; Andriani, A; Bagnato, A; Breccia, M; Cedrone, M; Ciccone, F; De Muro, M; Di Veroli, A; Latagliata, R; Leonetti, SC; Maurillo, L; Montagna, C; Montanaro, M; Montefusco, E; Niscola, P; Porrini, R; Rago, A; Spadea, A; Spirito, F | 1 |
2 other study(ies) available for deferasirox and Cirrhosis
| Article | Year |
|---|---|
Association between renal iron accumulation and renal interstitial fibrosis in a rat model of chronic kidney disease.
Topics: Animals; Benzoates; Blood Pressure; Deferasirox; Fibrosis; Gene Expression; Iron; Iron Chelating Agents; Kidney; Male; Nephrectomy; Nephritis, Interstitial; Proteinuria; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Triazoles | 2015 |
Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase.
Topics: Aged; Benzoates; Chelation Therapy; Deferasirox; Erythrocyte Indices; Erythropoiesis; Female; Fibrosis; Follow-Up Studies; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myeloproliferative Disorders; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles | 2016 |